Pilot study to evaluate glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the general ward
- Conditions
- E11Type 2 diabetes mellitus
- Registration Number
- DRKS00015119
- Lead Sponsor
- niv.-Klinik für Innere MedizinKlinische Abteilung für Endokrinologie und Diabetologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Informed consent obtained after being advised of the nature of the study
Male or female aged =18 years
Type 2 diabetes (treated with diet, oral agents, non-insulin injected anti-diabetic medicine, insulin therapy or any combination of the four) or newly diagnosed hyperglycemia which requires s.c. insulin therapy
Type 1 diabetes, gestational diabetes
Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient
continuous subcutaneous insulin infusion (CSII)
hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
Pregnancy
Any mental condition rendering the patient incapable of giving his consent
Known or suspected allergy to insulin degludec or insulin aspart
Continuous parenteral nutrition
Participation in another trial which can influence outcome of the trial
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured = 24 hours after start of therapy
- Secondary Outcome Measures
Name Time Method